The new device addresses a long-standing limitation of existing tumour-on-chip models, which typically rely on manually loaded hydrogels and fixed architectures that make it difficult to separate the contributions of matrix properties, cellular organisation and soluble signalling to tumour cell behaviour. The researchers designed a resin-printed microfluidic chip with a central culture chamber measuring 12 by 8 millimetres and one millimetre in height, connected to inlet and outlet microchannels, with an optimised non-rectangular geometry to improve filling and reduce bubble trapping. After screening three commercial photopolymer resins for geometric fidelity and cytotoxicity, the team selected BioMed Clear, which supported 84.74 percent cell viability in direct contact assays compared with only 12.15 percent for the worst-performing resin. Imaging is performed through a bonded glass coverslip at the bottom of the device rather than through the resin itself, which minimises autofluorescence and optical artefacts. In flow tolerance testing, the assembled chips withstood perfusion rates from 0.05 to 80 millilitres per minute without leaks or delamination, demonstrating mechanical robustness far beyond routine culture requirements.

The heart of the platform is in situ digital light processing bioprinting, in which a top-down projector illuminates the hydrogel precursor inside the chip through a transparent PDMS lid, photopolymerising defined patterns layer by spatial definition rather than by layer accumulation. Sequential loading, exposure and washing steps allow different bioinks to be printed one after another into the same chamber, generating multicompartment structures in which each region contains a distinct cell population or matrix condition. Because the projected image determines the position, geometry and light dose of every region, the researchers can change the entire experimental design without redesigning the chip, fabricating new moulds or transferring preformed gels. A proof-of-concept print using three visually distinguishable materials confirmed that the workflow produces cleanly separated central cores, intermediate rings and outer rings within the device, establishing that the chip supports controlled multi-material patterning with spatial precision at the sub-millimetre scale.

Formulating the bioink required balancing biological complexity against printability. Gelatin methacryloyl, or GelMA, was chosen as the structural backbone because it crosslinks under visible light, carries cell-adhesive motifs derived from its gelatin origin and allows mechanical tuning. Because GelMA alone does not capture the biochemical richness of the tumour extracellular matrix, the researchers incorporated Matrigel, a basement membrane extract, and type I collagen, the principal fibrillar protein of stromal tissue. Screening metabolic activity of encapsulated HCT116 colorectal cancer cells revealed a clear composition-dependent response: higher GelMA concentrations reduced activity while increasing Matrigel content enhanced it, and the addition of a low concentration of collagen further improved the cellular response. The final formulation of 5 percent GelMA, 15 percent Matrigel and 0.2 percent type I collagen produced a soft hydrogel with an apparent compressive modulus of approximately 2.11 kilopascals, a value squarely within the range reported for soft tumour and stromal microenvironments in human colon tissue.

Perhaps the most elegant technical feature of the platform is its use of greyscale-controlled exposure to tune matrix mechanics without changing the bioink’s chemical composition. Because the photocrosslinking density of a hydrogel depends on the delivered light dose, the researchers can adjust stiffness simply by dimming the projected image. Calibrated measurements on a 4K digital light processing projector showed a nearly linear relationship between greyscale level and irradiance at the printing plane, and four conditions at 100, 75, 50 and 25 percent projected intensity delivered irradiances from 6.776 down to 1.898 milliwatts per square centimetre over 45-second exposures. This optical dial tuned the apparent compressive modulus of the identical bioink from 2.11 kilopascals at full intensity down to 0.43 kilopascals at quarter intensity, while rhodamine B diffusion measurements confirmed that apparent diffusivity increased correspondingly from 4.95 to 6.21 times ten to the minus six square centimetres per second. In other words, a single bioink can now be printed across a continuum of mechanically distinct microenvironments within the same experiment.

To verify that the transport properties of these soft matrices were compatible with static culture, the team performed finite element simulations in COMSOL Multiphysics using the experimentally measured diffusion coefficients. One model tracked how concentration gradients relax within the printed hydrogel domains, confirming that the Matrigel- and collagen-containing formulations reach equilibrium faster than GelMA alone. A second model coupled glucose diffusion with cellular consumption described by Michaelis-Menten kinetics, simulating nutrient depletion over four days at different cell densities. These calculations established that a working density of one million cells per millilitre was conservative for the short-term experiments, ensuring that the observed cellular behaviour would reflect matrix and co-culture effects rather than metabolic starvation.

The biological experiments exploited both variables of the platform simultaneously. Using fluorescently labelled cells, the researchers printed concentric structures comprising a central HCT116 tumour core 0.5 millimetres in diameter, a surrounding ring of human umbilical vein endothelial cells 100 micrometres thick and an outer acellular ring completing a one-millimetre construct. Tumour-only controls replaced the endothelial ring with cell-free bioink. One construct was printed at each of the four greyscale conditions within every chip, allowing matrix stiffness and cellular organisation to be compared in a single device. Over four days of static culture, fluorescence imaging revealed that HCT116 cells progressively redistributed outward from the printed core, and quantitative image analysis showed that this movement depended strongly on both variables. Two-way statistical analysis found a significant interaction between light dose and culture configuration, with the co-cultured constructs showing markedly greater redistributed areas at 50, 75 and 100 percent intensity, and the strongest response occurring at 75 percent projected intensity.

The magnitude of the endothelial effect was striking: the mean redistribution distance of HCT116 cells increased from 48 micrometres in tumour-only constructs to 101 micrometres when the HUVEC compartment was present, an overall increase driven by paracrine chemotactic signalling that is well documented in co-culture studies of tumour-endothelial interaction. Crucially, live/dead staining on day four showed high viability of both cell types across all greyscale conditions with no significant intensity-dependent differences, confirming that the redistribution patterns arose from genuine matrix- and co-culture-dependent behaviour rather than printing-induced cytotoxicity. The authors note that the aim was not to present a fully established model of invasion but to demonstrate that the platform can monitor early tumour cell redistribution from a defined initial geometry under controlled, experimentally variable conditions.

The significance of this work lies in its integration. Direct in-chip bioprinting, sequential multi-material patterning, light-dose modulation and fluorescence-based monitoring have previously existed as separate capabilities, but combining them within one microfluidic workflow creates a genuinely reconfigurable system in which geometry, stiffness, composition and cellular architecture can each be varied independently. Because greyscale exposure alters crosslinking density while keeping ligand density, viscosity and biochemical composition constant, matrix mechanics can now be interrogated as an isolated variable in tumour cell behaviour, something composition-based approaches cannot achieve cleanly. The platform also opens a path toward future versions incorporating perfusion, endothelial barrier measurements, drug-loaded hydrogel compartments and nanocarrier delivery, consistent with emerging hydrogel-based approaches for colorectal cancer therapeutics.

For the broader field of cancer research, the study offers a versatile, controlled tool for dissecting how microenvironmental architecture shapes the earliest steps of metastatic behaviour, the stage at which therapeutic intervention remains most effective. As the authors conclude, the goal is to enable mechanistic studies of migration, invasion, endothelial interaction and therapeutic response under better-defined tumour-microenvironmental conditions, moving the field beyond the limitations of flat plastic and toward models that honour the true three-dimensional complexity in which cancer cells live, move and invade.

The central problem these platforms address is the tumor microenvironment, the dynamic and immunosuppressive niche that governs cancer progression, immune evasion, and therapeutic resistance. Tumors are not merely masses of malignant cells; they are complex ecosystems containing cancer stem cells, stromal cells such as fibroblasts and endothelial cells, angiogenic vessels, extracellular matrix, signaling molecules, and a diverse cast of immune populations including macrophages, dendritic cells, neutrophils, natural killer cells, B cells, and T cells. Within this milieu, regulatory T cells, myeloid-derived suppressor cells, and elevated checkpoint molecules conspire to blunt anti-tumor immunity. The review frames tumor–immune dynamics through the cancer immunoediting framework of elimination, equilibrium, and escape, emphasizing that immune evasion during the escape phase is what allows clinically detectable malignancy to emerge and that the microenvironment is an active driver of tumor evolution and therapeutic resistance rather than a passive backdrop.

Immunosuppression within the tumor microenvironment operates through multiple mechanistic layers. An immunosuppressive cytokine milieu dominated by TGF-β, IL-10, and IL-6 suppresses T cell activation while promoting the expansion of myeloid-derived suppressor cells and M2-polarized macrophages. Chemokine gradients, including CCL22 and the CXCR4/CXCL12 axis, actively recruit suppressive cell populations to the tumor site while excluding cytotoxic effector cells, creating spatially organized immunosuppressive niches that shield tumor cells from immune destruction. Tumor-associated macrophages, among the most abundant and plastic immune populations in the microenvironment, are typically driven toward a pro-tumorigenic M2 phenotype through IL-4, IL-13, and IL-10 signaling, converting a potentially anti-tumor force into an active promoter of progression and therapy resistance. Tumors are further classified as inflamed or hot, immune-excluded, or immune-desert or cold, with the latter two categories being largely refractory to immunotherapy, a reality that underscores why models preserving spatial and stromal complexity are so valuable.

At the heart of immune evasion lies the exploitation of checkpoint pathways. PD-L1 on tumor cells engages PD-1 on T cells, inducing a state of exhaustion characterized by reduced proliferation, cytokine production, and cytotoxicity, while CTLA-4 dampens T cell priming by competing with CD28 for B7 ligands. Emerging checkpoints including LAG-3, TIM-3, and TIGIT further contribute to intratumoral T cell exhaustion and represent targets for next-generation immunotherapy. Immune checkpoint inhibitors have demonstrated efficacy across a remarkable range of malignancies, including non-small cell lung cancer, urothelial bladder cancer, head and neck squamous cell carcinoma, breast cancer, cutaneous squamous cell cancer, melanoma, renal cell cancer, and Hodgkin’s lymphoma. Yet predicting which patients will benefit remains difficult, which is precisely where co-culture platforms that preserve viable immune cells alongside living tumor tissue promise to change clinical practice.

The review traces the evolution of cancer models from flat two-dimensional monolayers, which advanced early understanding of tumor biology but fail to capture complex tumor–microenvironment interactions, to three-dimensional systems that more accurately recapitulate in vivo tumor structure and behavior. Gene expression profiling of three-dimensional multicellular tumor spheroids has revealed upregulation of hypoxia-responsive genes and downregulation of cell cycle-related genes compared to two-dimensional models, and enhanced mevalonate pathway activity has been observed in quiescent spheroid cells, underscoring the context-dependent nature of anticancer responses in 3D. Spheroids, typically 200 to 500 micrometers in diameter, form through integrin- and cadherin-mediated self-assembly and can be generated by pellet culture, hanging drop, liquid overlay, or spinner techniques, each with distinct trade-offs in scalability, monitoring, and hypoxic core formation. When co-cultured with immune cells such as PBMCs, spheroids enable modeling of tumor–immune interactions and intratumoral heterogeneity, making them a valuable preclinical research tool.

Organoids, often described as mini-organs, go further by self-organizing to recapitulate native tissue architecture and function through lineage commitment and spatial cell sorting guided by extracellular matrix and culture medium cues. Patient-derived tumor organoids have now been generated across colorectal, pancreatic, breast, lung, and brain cancers, among others, retaining the mutational profiles, histopathology, and cellular diversity of the source tumor. Matrigel-based systems remain the most widely used due to accessibility and standardized workflows, despite batch-to-batch variability, while bioengineered synthetic matrices offer tunable stiffness and improved reproducibility at higher cost. Advanced technologies are pushing the field further: microfluidic organ-on-a-chip systems enable perfused, vascularized organoids modeling fluid flow and immune infiltration; air–liquid interface culture preserves epithelial, stromal, and immune components with improved oxygenation; and microwell arrays, droplet encapsulation, and acoustic aggregation enable high-throughput, size-controlled production, though typically limited to short-term culture.

The translational centerpiece of the review is the PDTO–PBMC co-culture system, which the authors describe as enabling reconstitution of autologous immune responses in an antigen-agnostic manner. The landmark study by Dijkstra and colleagues established that co-culturing peripheral blood lymphocytes with tumor organoids expands CD8-positive T cells that kill tumor organoids but spare healthy tissue-derived organoids, with killing efficiency of 20 to 80 percent depending on tumor type, and confirmed antigen-specificity through HLA-blocking experiments. The review is careful to define what constitutes genuine functional immune reconstitution rather than mere physical co-localization: HLA-dependent tumor-selective killing, CD137 upregulation as a marker of tumor-reactive T cell activation, interferon-gamma secretion, and granzyme B-mediated cytotoxicity must all be demonstrated. Checkpoint blockade responsiveness has been validated in immune-enhanced organoid platforms, with anti-PD-1 treatment increasing CD3-positive and CD8-positive T cell recruitment, and air–liquid interface models showing organoid responses to PD-1/PD-L1 blockade correlating with clinical outcomes in approximately 85 percent of cases.

Beyond T cells, the platforms extend across the immune repertoire. Cancer-associated fibroblasts co-cultured with organoids enhance tumor growth, promote epithelial–mesenchymal transition, and confer therapy resistance across colorectal, pancreatic, hepatocellular, and esophageal cancers, while endothelial co-culture illuminates tumor-induced angiogenesis and vascular niche-dependent drug resistance. Macrophage co-cultures reveal that sirtuin-1 promotes M2 polarization and suppresses CD8-positive T cell activity in colorectal cancer, and that the CCL5–Sp1–AREG axis mediates tumor–macrophage crosstalk in pancreatic cancer. Dendritic cell co-cultures expose tolerogenic shifts in tumor microenvironments, and natural killer cell studies in breast and pancreatic cancer models have demonstrated both therapeutic potential and tumor-induced immune impairment. CAR T cell evaluation has been particularly transformative: patient-derived bladder cancer organoids have been validated as reliable preclinical platforms for CAR T testing, neuroblastoma organoids have modeled CAR T infiltration and antigen loss, and glioblastoma organoids now serve as real-time avatars for assessing responses to clinical CAR T cell therapy.

The review does not shy away from sobering limitations. Most published work remains at the proof-of-concept stage, with prospective clinical validation data still sparse and no defined response thresholds for what magnitude of in vitro cytotoxicity reliably predicts clinical benefit. Organoid establishment success rates vary dramatically, from 22 percent rising to 75 percent with optimized protocols in metastatic colorectal cancer, 58 percent in pancreatic cancer, and as low as 17 percent for conventional lung cancer protocols versus over 90 percent with optimized free-floating platforms. PBMC viability after cryopreservation, delays exceeding 24 hours between blood collection and processing, and inter-patient immune repertoire variation all confound outcomes. Turnaround from biopsy to functional readout typically spans three to six weeks, though accelerated platforms have demonstrated feasibility within 7 to 14 days. Clonal evolution poses a further threat, as culture-adapted subclones may displace clinically relevant immune-evasive populations, and therapy-induced changes can alter neoantigen repertoires and checkpoint expression. The authors call for the newly proposed Minimum Information about Organoid Research reporting standard, reference organoid lines, external quality control programs, and a structured evidentiary roadmap toward companion diagnostic status under FDA and EU IVDR frameworks.

Looking forward, the convergence of microfluidics, spatial transcriptomics, single-cell multi-omics, and artificial intelligence promises to expand both the biological fidelity and translational utility of these platforms. Three-dimensional bioprinting allows spatially controlled deposition of tumor, immune, and stromal components that better recapitulate immune exclusion zones and stromal barriers, while machine learning applied to high-dimensional co-culture datasets holds promise for predicting patient-specific immunotherapy responses. The authors conclude that clinical validation of tumor–immune co-culture systems will be fundamental to achieving truly personalized cancer immunotherapy, in which each patient’s tumor is prospectively tested against their own immune cells to guide individualized treatment decisions, transforming organoid co-culture from a research curiosity into a functional companion diagnostic for precision oncology.

Subject of Research: Patient-derived tumor organoid co-culture systems for modeling tumor–immune interactions and evaluating cancer immunotherapy and precision oncology

Article Title: Patient-derived tumor organoid co-culture systems as translational platforms for cancer immunotherapy and precision oncology

Article References: Gadelkarim, M., Elsayed, A., Abaza, T., Bahr, A. R., Elsayed, Y., & Iqbal, O. (2026). Patient-derived tumor organoid co-culture systems as translational platforms for cancer immunotherapy and precision oncology. Clinical Cancer Bulletin, 5(1), Article 18. https://doi.org/10.1007/s44272-026-00067-1

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00067-1

Keywords: tumor organoids, co-culture, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, CAR T cells, PBMC, precision oncology, patient-derived models, adoptive cell therapy, organ-on-a-chip, companion diagnostics

The core idea is to implant fluorescently labeled human glioblastoma organoids (GBOs) into organotypic human brain slices. This pairing allows malignant cells to invade within a realistic brain microenvironment while maintaining the genetic integrity and cytoarchitecture of both partners. In doing so, the model targets the long-distance communication concept that underlies glioblastoma as a “whole-brain” disease.

To visualize infiltration across the full range—from the initial contact region to single-cell dispersion—the workflow combines tissue expansion with light-sheet fluorescence microscopy. Light-sheet imaging provides high-resolution, three-dimensional views across thick samples, capturing the invasive front without compressing the biological context.

Technically, Core2Edge begins with brain slice preparation, typically taking about 4–6 hours depending on how many slices are handled. The GBOs are then prepared and cultured for roughly one day for initial maintenance before staining and transplantation into the slices. After implantation, a variable culture period of up to 10 days is used to allow invasion to progress to deeper regions.

Following imaging readiness, the samples are fixed for around 8 hours to stabilize tissue architecture for downstream microscopy. Once the GBOs are prepared, the protocol as a whole runs approximately 7–12 days, bridging organoid biology with slice-based invasion dynamics.

Because GBO-derived cells can be tracked fluorescently, researchers can quantify early infiltration steps and focus on cell–cell interactions at the tumor–microenvironment interface. The platform is also positioned for mechanistic studies of invasive progression and for evaluating how therapeutic candidates affect both core invasion and edge dissemination.

Importantly for translational research, Core2Edge supports drug screening and testing in a human-relevant context, potentially reducing dependence on animal experiments for questions tied to infiltration and transcriptional variability.

By enabling comprehensive mapping of infiltration and preserving heterogeneity, Core2Edge provides a structured route to interrogate glioblastoma’s spatial biology—connecting transcriptional states with where and how tumor cells spread.

Subject of Research: Human ex vivo glioblastoma infiltration model

Article Title: Core2Edge: a human glioblastoma organoid–brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion.

Article References: Melhem, A., Pregler, B.E.F., Rodriguez-Gatica, J.E. et al. Core2Edge: a human glioblastoma organoid–brain slice model capturing infiltration and transcriptional heterogeneity from core to single-cell dispersion. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01412-3

DOI: https://doi.org/10.1038/s41596-026-01412-3

Image Credits: AI Generated

Keywords: glioblastoma, organoids, organotypic brain slices, infiltration modeling, light-sheet fluorescence microscopy, ex vivo platform, drug screening, transcriptional heterogeneity

Lymphoid malignancies encompass a diverse array of hematologic cancers, including various forms of lymphoma and leukemia. Their heterogeneous nature and intricate interplay with surrounding stromal cells have long posed significant challenges for effective disease modeling. Conventional 2D cultures, while simple and cost-effective, fall short in replicating the spatial and mechanical cues essential for authentic tumor behavior. In contrast, 3D culture systems mimic the extracellular matrix, cellular heterogeneity, and oxygen gradients, providing a more physiologically relevant platform. This leap in fidelity results in more predictive models, yielding data that better translate to clinical settings.

The architecture of 3D cultures varies widely, ranging from scaffold-based hydrogels embedded with extracellular matrix components to scaffold-free spheroids and organoids. These systems enable cells to inhabit environments that closely emulate the stiffness, porosity, and biochemical signaling present in vivo. As a result, cell proliferation, differentiation, and drug responsiveness observed in 3D cultures are strikingly similar to patient-derived tissues. Notably, lymphoid malignancies often provoke dynamic remodeling of their niche, a phenomenon more accurately recapitulated in these advanced models, allowing researchers to dissect tumor-stroma crosstalk with high precision.

A key challenge in hematology is the frequent discordance between preclinical findings and clinical outcomes. Drugs that demonstrate efficacy in 2D culture or animal models frequently falter in human trials, underscoring the need for more predictive platforms. 3D culture systems, especially those incorporating patient-derived cells, bridge this translational gap by offering models that better simulate human tumor biology and microenvironmental influences. This advancement facilitates the identification of novel therapeutic targets and the evaluation of drug resistance mechanisms that were previously masked in oversimplified systems.

Several cutting-edge 3D culture modalities are making significant strides in lymphoid malignancy research. Patient-derived organoids, for example, preserve the genetic and epigenetic landscape of the original cancer tissue, enabling personalized medicine approaches. Co-culture systems integrating immune cells and stromal components permit investigation of immune evasion tactics employed by malignant clones. Meanwhile, microfluidic devices—organ-on-a-chip platforms—recreate dynamic fluid flows and nutrient gradients, providing another layer of physiological relevance. These innovations collectively foster a deepened understanding of lymphoid cancer pathogenesis.

The integration of multi-omics technologies with 3D cultures is catalyzing transformative discoveries. Single-cell RNA sequencing and spatial proteomics analyses of 3D tumor models reveal heterogeneous cellular states and uncover rare subpopulations contributing to disease progression and relapse. Such detailed molecular characterization within an accurate microenvironmental context is invaluable for designing targeted interventions. Moreover, real-time imaging and biosensor technologies embedded in 3D cultures enable longitudinal monitoring of cellular responses and metabolic shifts, offering kinetic insights impossible to capture in static 2D models.

From a therapeutic perspective, 3D culture systems are revolutionizing drug screening pipelines. High-throughput screening of chemotherapeutics, targeted agents, and immunotherapies in these platforms offers more robust assessments of efficacy and toxicity. Importantly, resistance mechanisms that arise from cell-cell interactions or extracellular matrix barriers—critical in lymphoid malignancies—are faithfully reproduced, aiding in the identification of combination therapies to circumvent treatment failure. This approach accelerates biomarker discovery and facilitates stratification of patient cohorts to optimize clinical outcomes.

One fascinating aspect of lymphoid malignancies is their dependency on the tumor microenvironment (TME), comprising fibroblasts, endothelial cells, immune infiltrates, and extracellular matrix components. Traditional 2D culture strips away much of this complexity, providing an incomplete picture of disease biology. In contrast, 3D models embed malignant cells within a dynamic, interactive milieu that sustains paracrine signaling, cellular crosstalk, and metabolic interplay. This enhanced microenvironmental mimicry uncovers novel pathways underpinning tumor survival, dissemination, and immune suppression, opening new avenues for therapeutic intervention.

Despite their numerous advantages, 3D culture systems are not without limitations. The increased complexity and cost compared to 2D cultures necessitate optimized protocols and standardization to ensure reproducibility. The integration of multiple cell types requires meticulous cell sourcing and validation to avoid artifacts. Furthermore, the scalability of certain 3D models poses challenges for widespread drug screening applications. However, ongoing advances in biomaterials, automation, and computational modeling are steadily overcoming these barriers, making 3D culture systems increasingly accessible to hematology researchers worldwide.

Importantly, the adoption of 3D culture models in preclinical research is reshaping clinical trial design and patient management. By providing more accurate predictors of patient response, these models could reduce the high attrition rates seen in oncology drug development. Personalized organoid cultures derived from patient biopsies are beginning to inform treatment decisions in real time, embodying the promise of precision medicine. Moreover, the ability to model rare lymphoid malignancies in vitro enhances opportunities for targeted drug development where animal models are lacking or insufficient.

The interdisciplinary nature of 3D culture technology development, involving biomaterials scientists, engineers, chemists, and clinicians, is fostering a vibrant research ecosystem. Collaborative centers specialize in integrating biological data with computational models to simulate tumor growth and predict therapeutic outcomes. Such systems biology approaches complement empirical data, enabling hypothesis-driven experimentation and accelerating discovery. The complexity captured by combining these modalities moves the field closer to replicating the human disease state ex vivo, thus transforming translational hematology.

Looking forward, the integration of artificial intelligence (AI) and machine learning (ML) with 3D culture experimentation holds tremendous potential. Automated image analysis and pattern recognition algorithms can rapidly identify phenotypic changes and drug responses at scale. Predictive models trained on multi-modal datasets derived from 3D systems can uncover hidden correlations and novel biomarkers of prognosis and treatment sensitivity. By enabling data-driven decision-making, these technologies will enhance the precision and efficiency of both research and clinical applications in lymphoid malignancies.

In parallel, innovations in microfabrication and bioengineering are giving rise to increasingly sophisticated organ-on-chip platforms that incorporate vascularization and immune system components. These dynamic models recreate physiological shear stresses and intercellular communications integral to tumor progression and immune modulation. Coupled with real-time biosensing, these systems provide granular control and monitoring, enabling unprecedented probing of hematologic malignancies in an accessible and manipulable setting. Such progress paves the way for transformative insights into cancer biology.

Educational efforts are essential to widen adoption and understanding of 3D culture systems among hematologists and oncologists. Workshops, dedicated courses, and collaborative networks disseminate protocols and best practices, bridging the gap between discovery science and clinical application. Funding initiatives targeting translational research promote integration of 3D models into drug development pipelines, ensuring sustained momentum. As these models become incorporated into standard practice, the landscape of lymphoid malignancy research and therapy is poised for a paradigm shift.

In conclusion, the rise of 3D culture systems represents a revolutionary advancement in modeling lymphoid malignancies. These next-generation platforms bridge longstanding gaps between laboratory models and human disease, faithfully recapitulating the complex tumor microenvironment and cellular heterogeneity. By enabling precise dissection of tumor biology, enhancing drug screening fidelity, and facilitating personalized medicine, 3D cultures are fundamentally reshaping translational hematology. The convergence of bioengineering, molecular biology, and computational analytics heralds a new era of cancer research with transformative potential for patient outcomes.

Subject of Research: Lymphoid malignancies and advanced 3D culture systems in translational hematology

Article Title: Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology

Article References:
Houmera, N., Genestier, L. & Huet, S. Next-generation models for lymphoid malignancies: the rise of 3D culture systems in translational hematology. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03487-x

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03487-x (Published 03 June 2026)

Traditional models for bladder cancer, including two-dimensional cell cultures and animal models, have faced persistent limitations due to their inability to faithfully recapitulate the intricate architecture and cellular dynamics of the human bladder. Tumor heterogeneity, interaction with the surrounding healthy tissue, and the biochemical cues within the urothelial niche are often lost or misrepresented outside the human physiological context. Addressing these challenges, the researchers adopted an advanced tissue engineering strategy, cultivating spheroids—three-dimensional aggregates of cancer cells—that retain native tumor features such as hypoxia gradients, cellular heterogeneity, and extracellular matrix deposition.

What sets this model apart is the deliberate integration of these bladder cancer spheroids into an engineered, stratified human urothelium, representing the multilayered epithelial lining that naturally constitutes the inner surface of the bladder. The urothelium is not merely a physical barrier but a dynamic interface involved in signaling, tissue regeneration, and defense mechanisms. By embedding cancer spheroids into this milieu, the model faithfully reproduces critical tumor-stroma interactions, which are vital for understanding tumor progression, invasion, and therapeutic resistance. This spatial architectural mimicry enhances the physiological relevance, enabling researchers to capture the interplay between malignant and non-malignant cell populations.

Construction of the in vitro model involved meticulous optimization of cellular sourcing, growth conditions, and scaffold materials. Primary urothelial cells derived from healthy human donors were cultured to form a differentiated, multilayered epithelium on a biocompatible substrate that mimics the bladder extracellular matrix. Concurrently, bladder cancer cells were cultured to generate spheroids exhibiting representative tumor features. The subsequent co-culture involved seeding the spheroids onto the urothelial model at precise spatial configurations, ensuring optimal integration without compromising the integrity of the healthy epithelium. This process allowed real-time observation of tumor-epithelium crosstalk under controlled laboratory settings.

A key innovation lies in the model’s capability to sustain prolonged viability and functional activity of both tumor spheroids and urothelium, overcoming previous hurdles where co-cultures often suffered rapid deterioration or loss of differentiated features. The researchers employed advanced bioreactors and media formulations to provide dynamic perfusion and nutrient exchange, closely mimicking in vivo physiological conditions. The resulting model demonstrated sustained cell viability, maintenance of differentiation markers in the urothelium, and preservation of tumor cell proliferation and invasion capacity for extended periods, thereby offering a robust platform for longitudinal studies.

Functionally, the integrated model was rigorously validated through histological, molecular, and functional assays. Immunohistochemical staining confirmed the preservation of urothelial differentiation markers such as uroplakins and tight junction proteins, essential for barrier function, alongside expression of tumor-specific markers within the spheroids. Gene expression profiling revealed that key signaling pathways involved in tumor progression and epithelial homeostasis were active in a manner congruent with human disease states. Moreover, live imaging techniques documented dynamic cellular behaviors including tumor cell invasion into healthy tissue layers—a hallmark of cancer aggressiveness.

Perhaps most compellingly, the model displayed remarkable utility in preclinical therapeutic testing. The study assessed the response of bladder cancer spheroids to clinically relevant chemotherapeutic agents and targeted therapies, within the context of the healthy urothelium. This setting unveiled nuanced drug responses that were previously unattainable, including differential sensitivity rooted in tumor-stroma interactions and epithelial barrier effects on drug penetration. Such findings underscore the model’s capacity to predict patient-like responses more accurately than standard cultures, guiding personalized medicine approaches and the development of improved pharmacological regimens.

The innovation extends towards scalability and adaptability, vital for widespread research applications and pharmaceutical development pipelines. The system can be customized by incorporating patient-derived cancer cells, enabling personalized tumor models to test individual responses and resistance mechanisms. Additionally, the framework lends itself to integration with advanced imaging technologies, high-throughput screening, and multi-omics analysis, rendering it a versatile tool for oncology research and drug discovery.

The implications of this study reach far beyond bladder cancer. The modeling strategy exemplifies a blueprint for constructing organ-specific tumor-healthy tissue interfaces, addressing a central challenge in oncology—the need to study cancers within their native microenvironment. This approach could revolutionize how researchers investigate tumor biology, metastasis, immune evasion, and therapeutic resistance across diverse cancer types, fostering innovation in targeted therapies and combination treatments.

Moreover, the study highlights the importance of integrating human-relevant biological complexity into preclinical models to bridge the translational gap between bench and bedside. By faithfully reproducing human bladder architecture and cellular interplay, the model enhances the predictive power of laboratory findings, potentially reducing the high attrition rates seen in clinical trials due to insufficient preclinical efficacy or toxicity data.

In conjunction with emerging technologies such as artificial intelligence and organ-on-chip systems, this in vitro bladder cancer model could evolve further, incorporating immune components, vasculature, and mechanical forces inherent to the urinary bladder environment. Such advancements will deepen our understanding of tumor-host interactions and unveil novel therapeutic targets that may remain concealed in simpler models.

This research underscores the vital role of interdisciplinary collaboration, combining expertise in tissue engineering, cancer biology, molecular pathology, and pharmacology to confront the complexities of cancer modeling. It also sets the stage for future studies aimed at unraveling the multifaceted roles of the urothelium in tumor microenvironment modulation and treatment responses.

In summary, the development of an advanced in vitro bladder cancer model integrating cancer spheroids with a healthy human urothelium embodies a paradigm shift in cancer research. It offers a sophisticated, physiologically relevant platform to investigate tumor biology, evaluate therapeutic strategies, and ultimately improve clinical outcomes for bladder cancer patients. As researchers continue to refine this model and explore its potential, it stands as a beacon of innovation, epitomizing the fusion of biology and engineering to overcome longstanding barriers in cancer science.

Subject of Research: Development of an advanced in vitro bladder cancer model integrating bladder cancer spheroids with healthy human urothelium for improved preclinical therapeutic testing.

Article Title: An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing.

Article References:
Murray, B.O., Gao, J., Pasquina-Lemonche, L. et al. An advanced in vitro bladder cancer model integrating bladder cancer spheroids into a healthy human urothelium for preclinical therapeutic testing. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03476-0

Image Credits: AI Generated

DOI: 02 June 2026

ATLAS addresses a fundamental roadblock in metastasis research by enabling the generation of abundant cancer cell clusters under laboratory conditions that closely simulate the tumor microenvironment and circulatory system. Traditional methods often struggle with scalability, reproducibility, and faithfully replicating the mechanical and biological stresses experienced by metastatic clusters in vivo. The Rice team’s system stands apart by employing superhydrophobic surfaces, a concept inspired by natural water-repellent materials like lotus leaves. These surfaces cause liquid droplets containing cancer cells to form bead-like shapes rather than spread, promoting the aggregation of cells into three-dimensional clusters that retain critical physiological characteristics.

The underlying technology uses 3D-printed microwell arrays coated with nanoscale roughness and nonwetting substances such as Teflon to achieve superhydrophobicity. This design mimics natural water-repelling textures on a nanoscale and enables widespread scalability—a first in tissue engineering. This approach reduces time and cost significantly compared to prior superhydrophobic culture techniques, which relied on more labor-intensive fabrication methods. “Our use of 3D printing to form these specialized surfaces introduces a level of accessibility and reproducibility that could democratize this platform for laboratories globally,” Carter explained.

The ability to form large quantities of homogeneous cancer cell clusters is crucial when investigating the biophysical and biological mechanisms that enable metastatic cells to survive the harsh conditions of bloodstream circulation—characterized by shear stress and immune surveillance. The King lab’s long-standing focus on co-culturing cancer cells alongside stromal cells, particularly cancer-associated fibroblasts (CAFs), is key to understanding how tumor microenvironments promote metastatic success. Stromal cells, although noncancerous, influence tumor behavior and resilience dramatically, but their role in cluster survival within the vascular system has remained incompletely characterized.

By leveraging ATLAS, the Rice researchers created prostate cancer cell clusters, both with and without the inclusion of CAFs. Their experiments revealed that cancer clusters have a markedly higher survival rate when traveling as groups rather than as isolated cells, particularly when CAFs are present. These fibroblasts actively facilitate cancer cells’ endurance against the mechanical stressors of blood flow, enabling continuous growth and increased metastatic potential. This finding underscores the critical mechanobiological role of the tumor stroma in metastasis and offers novel avenues for targeted therapies aimed at disrupting this cellular symbiosis.

The insights gained from ATLAS extend beyond methodological advancements; they open promising biological pathways for combating prostate cancer metastasis. Carter emphasized the therapeutic implications: “Our study highlights that targeting the CAF ‘escorts’ accompanying cancer cell clusters could form the basis of next-generation treatments designed to prevent the dissemination of metastatic prostate cancer.” This concept challenges the conventional focus on cancer cells alone and shifts attention toward the supportive cells within the metastatic niche.

ATLAS exemplifies the power of integrating engineering principles with cancer biology to resolve longstanding experimental limitations. The platform sets new standards for studying the dynamic interactions within tumor microenvironments by closely recapitulating physiological blood flow and cellular architecture. Such realistic and high-throughput models will accelerate the development and testing of anti-metastatic drugs, potentially shortening timelines for preclinical research and enhancing translational success.

Alexandria Carter’s entrepreneurial spirit extends beyond the laboratory. Having completed Rice’s Innovation Fellows program, she is now founding a company named Bionostic to commercialize the ATLAS technology. This venture seeks to make the platform broadly available, transforming metastasis research and drug discovery efforts worldwide. The program, run by Rice’s Liu Idea Lab for Innovation and Entrepreneurship (Lilie), fosters such translation of academic inventions into practical solutions, reinforcing Rice’s commitment to impactful innovation.

Michael King, a prominent figure in bioengineering and a Cancer Prevention and Research Institute of Texas Scholar, echoed the importance of this advancement: “Studying metastasis has always been hindered by inadequate lab models. With ATLAS, we now have an elegant and scalable tool that deepens our comprehension of how cancer spreads, and that will ultimately guide the development of more effective therapies.” His leadership has been instrumental in bridging complex biological questions with cutting-edge material science and engineering techniques.

This new approach couldn’t come at a more critical time as metastatic prostate cancer continues to be one of the leading causes of cancer-related mortality. By uniting nanotechnology, 3D printing, and cellular mechanobiology, the Rice team has illuminated a crucial frontier—how the physical microenvironment and cellular partnerships dictate metastatic fate. The ATLAS system sets a precedent for future versatile models tailored to study different cancer types and microenvironmental factors.

With the patent-pending ATLAS technology, researchers now have at their disposal a scalable, cost-effective, and biologically relevant platform that could transform the exploration of metastatic mechanisms. These advances pave the way for discoveries that were previously out of reach due to technological and experimental constraints. Rice University’s breakthrough offers not just a glimpse into the cellular choreography of metastasis, but a robust tool to reshape cancer research and improve patient outcomes worldwide.

Subject of Research: Cancer metastasis modeling using engineered 3D cell culture systems
Article Title: A Superhydrophobic 3D Cell Culture System Reveals the Mechanobiological Role of Cancer-Associated Fibroblasts in Prostate Cancer Metastasis
News Publication Date: March 26, 2026
Web References: https://news.rice.edu/; http://dx.doi.org/10.1002/adhm.202600011
References: Carter A., Fabiano A., Aalaei E., Deng J., Rostant D., King M. (2026). A Superhydrophobic 3D Cell Culture System Reveals the Mechanobiological Role of Cancer-Associated Fibroblasts in Prostate Cancer Metastasis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202600011
Image Credits: Photo by Jared Jones/Rice University; Microscopy images courtesy of Alex Carter/Rice University; B-roll by Brandon Martin/Rice University
Keywords: Metastasis, Cancer, Prostate cancer, Superhydrophobicity, Cancer-associated fibroblasts, 3D cell culture, Shear stress, Blood flow, Tumor microenvironment, Nanotechnology, 3D printing, Mechanobiology

Enter the realm of organoids—three-dimensional, multicellular structures derived from stem cells that mimic the architecture and functionality of real organs. Over the past decade, organoid technology has revolutionized biomedical research by providing more physiologically relevant models than two-dimensional cell cultures or animal models. In neuro-oncology, the advent of brain tumour organoids represents a groundbreaking leap forward, offering unprecedented opportunities to capture the spatial, cellular, and molecular diversity of brain tumours in vitro. These tumour organoids serve as living avatars, embodying the unique profile of each patient’s malignancy while enabling controlled experimental manipulation.

Reviewing the latest advances, pioneering researchers have developed sophisticated methodologies to generate brain tumour organoids directly from patient-derived tumour samples across a spectrum of tumour types, including gliomas, medulloblastomas, and other central nervous system neoplasms. This approach preserves the genetic and epigenetic landscape of the original tumour, as well as key microenvironmental features such as cellular heterogeneity, extracellular matrix composition, and even immune cell infiltration in some models. As a result, these organoids provide an exquisitely faithful representation of tumour biology, far surpassing the limitations of traditional models.

Scientists have leveraged these organoid systems to dissect fundamental mechanistic questions about tumour initiation and progression. By capturing the early stages of tumour development within a controlled environment, researchers can observe how specific genetic mutations and cellular interactions drive oncogenesis. Moreover, the ability to manipulate the genome or microenvironment in organoids through cutting-edge tools such as CRISPR-Cas9 genome editing further elucidates the pathways underpinning tumour aggressiveness and therapy resistance. This growing mechanistic insight lays the groundwork for the identification of novel therapeutic targets and biomarkers.

Beyond foundational biology, brain tumour organoids are proving invaluable for functional drug screening and therapeutic stratification. The diverse cellular makeup and preserved tumor heterogeneity within organoids allow for a more accurate evaluation of drug efficacy and toxicity than cell lines or animal models. High-throughput platforms integrating organoids enable researchers to test numerous compounds or drug combinations rapidly, identifying tailored treatment regimens that maximize efficacy while minimizing adverse effects. Importantly, these platforms also facilitate the study of acquired resistance mechanisms, a scourge in brain tumour management, by enabling longitudinal treatment monitoring within the organoid culture.

In the clinical context, integrating organoid technology into patient care strategies is ushering in a new era of co-clinical trials. In these scenarios, tumour organoids derived from individual patients are generated parallel to standard clinical treatment, allowing for real-time assessment of therapy responsiveness. This dual approach has the potential to refine treatment selection dynamically, ensuring that patients receive the most effective interventions based on functional evidence rather than static molecular snapshots alone.

Furthermore, advances in bioengineering and microfluidics have expanded the sophistication of tumour organoid models. Incorporating vascular-like networks, immune cell populations, and stromal components into organoid cultures is enhancing their fidelity to in vivo conditions. Such integrated systems not only deepen our understanding of tumour-immune interactions but also open new avenues for testing immunotherapies and targeted treatments within a context that closely mimics human physiology.

Despite these exciting strides, challenges remain in standardizing organoid production and ensuring reproducibility across laboratories. The inherent variability associated with patient-derived materials, coupled with technical nuances in culture conditions, necessitates rigorous protocols and quality control measures. Addressing these issues is crucial for the widespread adoption of organoids as robust preclinical and clinical tools in neuro-oncology.

Looking forward, the convergence of single-cell multi-omics and organoid technology promises to unravel even greater layers of tumour complexity. By integrating genomics, transcriptomics, epigenomics, and proteomics at the single-cell level within organoids, researchers can capture dynamic cellular states and lineage trajectories that drive tumour behavior. This comprehensive molecular profiling will inform more precise therapeutic targeting and enable the discovery of previously unrecognized vulnerabilities.

The momentum of organoid research in brain tumours is catalyzing a paradigm shift in precision medicine, transforming how we model, understand, and treat these formidable malignancies. By faithfully recapitulating patient-specific tumour biology, organoids empower clinicians with actionable insights, accelerating the translation of laboratory discoveries into tangible clinical benefits. As this field continues to mature, it holds tremendous promise to significantly improve outcomes for patients afflicted with some of the most challenging and devastating cancers known.

In sum, brain tumour organoids are not merely experimental tools but are rapidly becoming integral components of the neuro-oncology precision medicine toolkit. They encapsulate the hope that personalized therapeutic strategies can be systematically developed and deployed based on a deep, mechanistic understanding of each tumour’s unique biology. With continued innovation and interdisciplinary collaboration, organoids may soon realize their full potential as transformative assets in the fight against brain cancer, heralding a new era of bespoke cancer therapy.

Subject of Research: Brain tumour modeling using organoids to advance precision medicine in neuro-oncology.

Article Title: Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.

Article References:

de Lucas Sanz, M., Niclou, S.P. & Golebiewska, A. Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.
Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01190-2

Image Credits: AI Generated

In recent years, 3D tumor models such as multicellular spheroids have revolutionized cancer research by providing a system that closely reproduces the heterogeneity and architecture of solid tumors. Unlike traditional two-dimensional (2D) cultures, 3D spheroids exhibit gradients of oxygen, nutrients, and metabolites, alongside dynamic cell-cell and cell-matrix interactions, offering a biologically relevant platform to study tumor behavior, drug sensitivity, and resistance mechanisms. However, the lack of standardization in spheroid formation techniques has been a critical bottleneck limiting reproducibility and translational relevance, a challenge that this IGTP study directly confronts.

The researchers systematically examined three prevalent methods for generating MCTS: liquid overlay, hanging drop, and U-bottom plates. Their comprehensive evaluation spanned eight colorectal cancer cell lines, reflecting the molecular and phenotypic diversity observed in patients. These methods were tested across various extracellular matrices, including Matrigel, collagen I, and methylcellulose, to determine how matrix composition influences spheroid morphology and compaction. Through quantitative imaging and morphological assessments, the team unveiled that both cell type and culture conditions profoundly impact spheroid architecture, emphasizing the complexity behind in vitro modeling of colorectal tumors.

One of the landmark outcomes of the study is the description of a novel compact spheroid model derived from the SW48 cell line. Historically categorized as non-spheroid-forming, SW48 has posed challenges for investigators aiming to establish 3D models that accurately recapitulate tumor biology. By optimizing culture parameters, the IGTP group demonstrated that SW48 cells could indeed form compact spheroids, expanding the repertoire of colorectal cancer models amenable to 3D culture-based investigations.

Importantly, the study highlights a cost-effective innovation: the application of an anti-adherent treatment to standard culture plates significantly improves spheroid formation, serving as a scalable alternative to expensive commercially available cell-repellent plates. This methodological refinement not only reduces barriers to widespread adoption but also promotes consistency across laboratories, thereby enhancing the comparability of experimental outcomes in preclinical cancer research.

Beyond monocultures, the IGTP team also explored the incorporation of colonic fibroblasts into co-culture spheroid systems. This addition underscores the significance of the tumor microenvironment, specifically tumor-stroma interactions, as fibroblasts play a crucial role in modulating cancer progression, extracellular matrix remodeling, and response to therapies. Their inclusion in 3D models elevates biological relevance, providing a more accurate simulation of in vivo conditions and better predictive value for translational studies.

Another intriguing discovery relates to morphological disparities observed between isogenic colorectal cancer lines, notably DLD1/HCT8 and SW480/SW620 pairs. Despite genetic similarity, differences in spheroid compactness and structure suggest that epigenetic or transcriptional regulation may be pivotal in shaping 3D tumor architecture. This insight opens avenues for further mechanistic studies into the molecular determinants of spheroid formation and stability, potentially revealing novel therapeutic targets.

The comprehensive nature of this study stems from months of systematic optimization and methodological rigor. As Dr. Sergio Alonso, last and corresponding author, emphasizes, this work aspires to serve as a practical guideline for researchers working with tumor spheroid models, fostering the harmonization of protocols that are currently diverse and fragmented. By addressing these technical disparities, the study paves the way for more robust, reproducible, and clinically relevant colorectal cancer research.

Given the increasing emphasis on precision medicine, this advancement holds promise for better predictive modeling of drug responses and resistance mechanisms. Three-dimensional spheroid cultures offer a platform compatible with high-throughput drug screening and mechanistic studies, thus expediting the preclinical evaluation pipeline for novel therapeutics targeted at colorectal cancer, a malignancy that remains a leading cause of cancer morbidity and mortality worldwide.

Furthermore, the integration of various matrices closely mimics the tumor’s extracellular environment, influencing not only physical characteristics but also cellular signaling pathways. This aspect is critical as the extracellular context can modulate gene expression, metabolic orientation, and ultimately treatment efficacy. The study’s stratified analysis of matrix effects provides a valuable framework for selecting culture conditions aligned with specific research goals, whether focusing on tumor biology or therapeutic evaluation.

In conclusion, the IGTP study represents an innovative and timely contribution that bridges technical refinement with biological insight. By championing standardized 3D culture methodologies and demonstrating novel spheroid models for colorectal cancer research, this work equips the scientific community with refined tools to capture tumor complexity and translate findings into meaningful clinical impact. The study’s implications transcend colorectal cancer, offering foundational approaches adaptable to other tumor types where 3D culture models are indispensable.

As the cancer research landscape evolves rapidly, such detailed comparative analyses foster collaborative efforts and accelerate discovery, ensuring that laboratory models keep pace with the intricacies of human disease. With growing interest in tumor microenvironment modeling, co-culture systems, and epigenetic regulation of tumor heterogeneity, studies like this mark the frontier of in vitro cancer modeling, setting new standards for experimental rigor and translational relevance.

Subject of Research: Cells

Article Title: Comparative analysis of 3D-culture techniques for multicellular colorectal tumour spheroids and development of a novel SW48 3D-model

News Publication Date: 29-Jul-2025

Web References: https://doi.org/10.1038/s41598-025-13588-x

Image Credits: IGTP

Keywords: Colorectal cancer, Cancer, Cell cultures, Three dimensional modeling

One of the fundamental limitations of current organoid-immune cell co-cultures is their incomplete simulation of the immune system’s remarkable complexity. Most existing models center around isolated immune cell populations—typically T cells or macrophages—providing insight into singular immune components but failing to capture the intricate, dynamic interplay among diverse immune subsets in vivo. The TME comprises a tightly regulated network of T cells, B cells, dendritic cells, natural killer (NK) cells, and myeloid-derived suppressor cells, all converging to influence tumour progression and therapeutic efficacy. This lack of immune diversity in organoid cultures inherently restricts their ability to predict long-term immunotherapy responses with accuracy.

Adding to the challenge is the absence of critical vascular components and extracellular matrix (ECM) elements that are indispensable for modelling physiological conditions such as nutrient gradients, hypoxia, and mechanical stress. These features play pivotal roles not only in the immune cascade but also in the pharmacokinetics and dynamics of anti-cancer drugs, particularly those targeting angiogenesis or hypoxia-related pathways. The inability to replicate these gradients compromises the assessment of many therapeutic agents’ sustained effects, underscoring an urgent need for models that incorporate stromal and vascular elements alongside immune diversity.

Recent technological strides offer hope for surmounting these barriers. Integrative approaches using microfluidic platforms and 3D bioprinting have demonstrated striking potential to reconstruct more physiologically relevant TMEs. Microfluidics enable the recreation of fluid flow and the establishment of nutrient and oxygen gradients, mimicking vascular perfusion at a microscale, whereas bioprinting allows for precise spatial organization of multiple cell types and ECM components. Nevertheless, both approaches confront intrinsic challenges such as scalability limits, long-term stability, and the replication of cellular heterogeneity and complexity. Ongoing innovations in device engineering, novel biomaterials, and hybrid systems are poised to refine these models further.

Concurrently, the advent of organ-on-a-chip technologies adds another layer of sophistication by recapitulating microenvironmental conditions within controlled platforms that integrate real-time monitoring. When coupled with organoid cultures, these devices facilitate the study of cellular interactions and drug responses under physiologically relevant mechanical and biochemical conditions, potentially bridging the gap between in vitro models and in vivo reality.

Artificial intelligence (AI) technologies also stand at the frontier of enhancing organoid model complexity and interpretability. Leveraging AI-driven data analysis can illuminate key interactions within the TME by predicting immune cell-tumour crosstalk and optimizing culture parameters to better emulate in vivo conditions. Deep learning algorithms have shown promising applications in high-throughput imaging analysis and organoid tracking, offering unprecedented granularity and efficiency in interpreting complex datasets. The integration of computational approaches with experimental systems promises to accelerate model refinement and the predictive utility of organoid platforms.

However, drug sensitivity testing using organoids still reveals critical shortcomings. Conventional assessments predominantly focus on tumor cell viability but overlook the multifactorial contributions from the microenvironment. Immune cells, stromal fibroblasts, and vascular elements modulate drug efficacy, often through immune suppression or activation pathways. For example, myeloid-derived suppressor cells and tumor-associated macrophages may secrete factors that blunt drug responses. Without replicating these interactions, organoid-based drug screens risk overestimating clinical efficacy or missing mechanisms of resistance rooted in the TME.

To elevate the predictive power of drug sensitivity assays, multidimensional platforms that incorporate readouts of immune activation, cytokine secretion, and vascular integrity are essential. Emerging 3D bioprinted organoids and genetically engineered models enable more faithful reconstruction of tumour architecture and genetic context yet remain constrained by challenges related to long-term culture stability and full immunological representation. The fusion of these advanced models with comprehensive immune co-cultures, real-time imaging, and multi-omics analyses will be critical for more accurate and clinically relevant drug screening.

Long-term stability in organoid cultures is another pivotal factor influencing their translational utility. Cell viability, phenotypic fidelity, and epigenetic profiles can deteriorate over extended periods due to limitations such as nutrient depletion, oxygen gradients, and waste accumulation, especially in larger constructs. While frequent media renewal mitigates these issues, it introduces operational complexity and cost concerns. The incorporation of synthetic hydrogels and advanced biomaterials with tunable mechanical and biochemical properties has shown promise in creating supportive matrices that enhance cell viability and replicate ECM remodeling dynamics native to tumours.

Moreover, dynamic culture systems featuring real-time control of oxygen tension and nutrient flux through microfluidic integration further bolster organoid stability. Automated platforms that minimize manual intervention reduce inconsistencies and human error, enhancing reliability and scalability. These innovations collectively improve the feasibility of long-term organoid maintenance, an essential condition for chronic drug exposure studies and investigation of acquired resistance mechanisms.

Despite these technological advances, the field grapples with persistent issues regarding reproducibility and standardization. Variability in sample sources, matrix compositions, culture conditions, and data analysis contributes to inconsistent results across laboratories, undermining confidence in cross-study comparisons and clinical applicability. Even organoids derived from the same patient may diverge in gene expression patterns and drug responses due to subtle differences in culturing techniques and microenvironmental fidelity.

Addressing these reproducibility challenges mandates the establishment of unified guidelines encompassing sample processing, media formulations, ECM characterization, and analytical pipelines. International consortia have begun developing nomenclature conventions, validation standards, and ethical frameworks to harmonize protocols across different organoid types, including those derived from pluripotent and adult stem cells. Nonetheless, further refinement is necessary to accommodate the diversity of tissue origins and maintain long-term culture fidelity.

Advanced matrices such as synthetic hydrogels play a crucial role in reducing batch-to-batch variations and offering precise control over mechanical and biochemical properties, ensuring consistent organoid morphology and function. In parallel, integrating AI-driven data analytics and automated culture systems promises to enhance protocol optimization, predictive modeling of growth kinetics, and identification of critical parameters influencing reproducibility. Such approaches will be instrumental in establishing organoids as robust platforms for clinical translation.

Material sourcing and cost considerations pose another substantial constraint on the widespread adoption of organoid technologies, especially for immunotherapy applications. Patient-derived autologous immune cells combined with tumor organoids provide the gold standard for simulating individual immune-tumour interactions but are restricted by accessibility, labor-intensive protocols, and substantial expense. The inherent biological variability among patient samples further complicates scalability and standardization.

To navigate these limitations, research has increasingly turned to commercially available immune and tumor cell lines, which offer stable, cost-effective alternatives amenable to high-throughput workflows. However, these lines often lack the personalized and pathological complexity of primary cells, potentially undermining translational relevance. The balance between scientific rigor and practical feasibility remains a delicate trade-off.

Emerging modalities such as 3D bioprinting and microfluidic organoid systems introduce additional layers of complexity and cost, often requiring specialized infrastructures and sophisticated biomaterials. Genetically engineered organoids enable the dissection of mutation-specific responses but demand precise gene-editing technologies, further elevating resource requirements.

Efforts to alleviate these barriers include the development of biobanks and centralized repositories that curate well-characterized patient-derived samples, facilitating broader accessibility and reproducibility. Additionally, AI-guided algorithms are being employed to streamline material selection by analyzing multi-omics datasets to identify representative cell sources and optimize experimental designs. As standardized repositories and computational tools mature, the scalability and affordability of organoid immunotherapy models are expected to improve significantly.

Looking forward, the convergence of organoid culture innovations with cutting-edge technologies such as microfluidics, gene editing, and artificial intelligence will usher in a new paradigm in precision oncology. Integrated platforms capable of simulating the full complexity of the tumour immune microenvironment and enabling rigorous, scalable drug testing hold the potential to transform personalized cancer treatment. While challenges remain, the steady progression of interdisciplinary research fuels optimism that organoid models will become indispensable assets in the fight against cancer.

Subject of Research: Organoid models in cancer immunotherapy, tumour microenvironment simulation, drug sensitivity testing, and personalized medicine.

Article Title: Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments.

Article References:
Wang, Q., Yuan, F., Zuo, X. et al. Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments. Cell Death Discov. 11, 222 (2025). https://doi.org/10.1038/s41420-025-02505-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02505-w

Cancer therapy has long faced the challenge of efficacy, notably in the translation of promising laboratory results into successful human treatments. Regrettably, therapies that demonstrate effectiveness during in vitro studies or in animal models often fail to yield the same results in humans. MIRO addresses this gap by not only replicating tumor characteristics but also simulating the complex interactions between tumors and immune cells within their microenvironment. This capability is crucial for developing successful immunotherapy treatments, as the immune response plays a pivotal role in determining treatment outcomes.

Dr. Anna Labernadie, who was instrumental in developing the MIRO microfluidic system during her postdoctoral research at IBEC, emphasized that the device enables researchers to observe how tumors interact with immune cells, revealing crucial details that could enhance treatment efficacy. The ability to recreate both the tumor and its environment allows scientists to better understand the dynamics of these interactions. Immunotherapies, which harness the power of the immune system to combat cancer, currently exhibit varying success rates, benefiting only 20 to 40 percent of patients. By utilizing MIRO, researchers can explore strategies to improve these rates significantly.

Among the initial applications of MIRO, researchers investigated samples from patients with HER2-positive breast cancer. Her2 is a protein known to promote aggressive tumor growth, and therapies targeting this protein have been developed. Preliminary data indicate that the microenvironment surrounding breast tumors significantly protects them from effective treatments, such as the monoclonal antibody trastuzumab. This protection is critical because it signifies that the tumor microenvironment can impede the action of immune therapies, contributing to treatment resistance.

Dr. Alexandre Calon, who leads the Translational Research Laboratory in Tumor Microenvironment at the Hospital del Mar Research Institute, noted the striking observations made possible by MIRO’s advanced capabilities. The studies demonstrated that immune cells exhibit diminished motility as they approach the tumor, ultimately becoming blocked by a barrier formed by the tumor microenvironment. This insight could inform new approaches to enhance the effectiveness of cancer treatments by addressing the mechanisms that restrict immune cell function.

MIRO is not limited to breast cancer research. This innovative device has demonstrated its versatility through successful applications in other solid tumors, including lung and colon cancers. By employing cutting-edge microfluidic techniques, MIRO allows for the precise manipulation of fluids and cells on a microscale, facilitating detailed experimentation in a controlled setting. Different cell cultures can be compartmentalized, allowing researchers to observe the dynamic interactions between cancer cells, their connective stroma, and immune responses.

The significance of this research lies in its potential to revolutionize personalized cancer treatment. Unlike traditional methods that adopt a one-size-fits-all approach, MIRO enables direct testing of therapies that could be employed with specific patients in real-time. Dr. Xavier Trepat, an ICREA research professor at IBEC, highlighted the extraordinary ability of this model: it can help researchers determine which treatment strategies are most likely to succeed based on individual tumor-stroma interactions.

The implications of MIRO extend beyond the laboratory. By identifying biomarkers unique to individual patients and analyzing the emergence of resistance mechanisms, this tool is poised to play a vital role in tailoring immunotherapy treatments. Dr. Joan Albanell, head of the Medical Oncology Service at Hospital del Mar, asserted that MIRO represents an innovative preclinical model that could significantly improve the success and efficacy rates of novel immunotherapy strategies before they undergo clinical trials.

As researchers look to the future, they intend to transfer MIRO technology to pharmaceutical companies and hospitals to facilitate its application in clinical settings. This transition is crucial for translating scientific discoveries into tangible patient benefits. Dr. Labernadie noted that a joint patent application has already been filed for MIRO’s technology, underscoring the commitment of IBEC, ICREA, and the Hospital del Mar Research Institute to advancing cancer treatment through innovation.

The MIRO initiative is part of a broader effort to understand the intricate roles of immune ecosystems in cancer progression. As evidenced by Alice Preucca’s PhD thesis work at IBEC, research is not deterred by the complexities of cancer biology; rather, it embraces them, recognizing that the interplay among various cellular components shapes disease progression and treatment response.

Collaboration has been a cornerstone of this project, with contributions from the Institute for Research in Biomedicine (IRB Barcelona), the University of Barcelona (UB), and other esteemed institutions enhancing the robustness of findings. The initiative further receives backing from various funding bodies, including the “la Caixa” Foundation and the Spanish Ministry for Science and Innovation, highlighting the multifaceted support that scientific research relies upon.

While the clinical application of MIRO is still underway, its potential to reshape cancer therapy is undeniable. The ongoing exploration of tumor dynamics, immune interactions, and personalized treatments heralds a new era in oncology, where patient outcomes may see unprecedented improvement. As researchers continue to unravel the complexities of cancer, tools like MIRO promise to bridge the gap between laboratory science and real-world therapeutic application, offering hope for more effective and individualized cancer treatments in the future.

Subject of Research: Human tissue samples
Article Title: Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing
News Publication Date: 3-Feb-2025
Web References: Nature Communications
References: N/A
Image Credits: Institute for Bioengineering of Catalonia (IBEC)

Keywords: Immunotherapy, Breast cancer, Colon cancer, Lung cancer, Stroma, Tumor microenvironments, Interleukins.